Canada’s Drug Agency and the Canadian Institute for Health Information signed an agreement to improve pharmaceutical data collaboration.

Agreement and Collaboration

Canada’s Drug Agency (CDA-AMC) and the Canadian Institute for Health Information (CIHI) have signed a 3-year agreement aimed at enhancing pharmaceutical data and analytics in Canada.

Objectives

The primary goal of this agreement is to strengthen the foundation of drug data and analytics across Canada. This will be achieved by leveraging the strengths of both organizations.

Scope of Work

The collaboration will focus on expanding CIHI’s pharmaceutical data holdings to support advanced analytics. These analytics will improve drug access, safety, and patient health outcomes.

Work Streams

The agreement aligns with the three new work streams announced by the federal government in December 2023 for Canada’s Drug Agency:
– Appropriate use of medications
– Data and analytics
– System coordination and alignment.

Stakeholder Involvement

The partnership will involve collaboration with federal, provincial, and territorial governments, as well as other key stakeholders to advance CIHI’s Pharmaceutical Roadmap.

Impact

This collaboration is expected to enhance the overall pharmaceutical system in Canada by providing better data-driven insights, reducing inefficiencies, and improving health outcomes.

This agreement reflects a broader effort to improve coordination, data collection, and analytical capabilities within Canada’s pharmaceutical sector. It aligns with the broader objectives of the Canadian Drug Agency Transition Office and national pharmacare initiatives. The pharmaceutical data collaboration effort is critical for achieving these goals.